MedTrace Logo

Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome

NCT02854917 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2018-01-25

No results posted yet for this study

Summary

This study is a retrospective review of the data collected in a previously completed randomized, controlled trial (RCT) entitled "Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial" (NCT00120874). As part of the previously completed RCT, participants with Alzheimer's Disease (AD) were randomly placed into one of two groups: memantine, or memantine plus an individualized management program consisting of home visits, educational sessions for caregivers, and a caregiver support group. Participants received the study intervention for 28 weeks; study follow-up lasted for 52 weeks.

The collected data from the existing study books from the 28 week treatment portion of the RCT will be carefully examined with respect to each of the research questions for the present retrospective study.

Conditions

  • Alzheimer Disease

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Fisher Center for Alzheimer's Research Foundation

    collaborator OTHER

  • NYU Langone Health

    lead OTHER

Principal Investigators

  • Barry Reisberg, MD · NYU Langone Health

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-01-05
Completion
2018-01-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02854917 on ClinicalTrials.gov